Why the study?
Does single bolus dose intracoronary eptifibatide reduce MACE and bleeding compared to bolus plus intravenous infusion in patients undergoing elective PCI?
Does single bolus dose intracoronary eptifibatide reduce MACE and bleeding compared to bolus plus intravenous infusion in patients undergoing elective PCI?
Intracoronary bolus infusion of eptifibatide alone may be a preferable strategy in elective PCI due to the use of lower doses with comparable efficacy and safety to bolus plus infusion.
Answers are grounded in this paper and cite their sources.
Should not yet change eptifibatide regimens in elective PCI; leaves open whether bolus-only dosing is equivalent.
BACKGROUND: Eptifibatide is a platelet glycoprotein IIb/IIIa receptor antagonist used for the prevention of cardiac ischemic complications of percutaneous coronary intervention (PCI). Eptifibatide has been used with bolus dose only or bolus plus infusion in patients undergoing PCI which have shown less complications, but the risk of bleeding has been increased. We aimed to compare the outcome and bleeding rate of bolus dose alone or plus infusion in elective PCI. METHODS: In this quasi-experimental study, we compared the outcome of elective PCI following single bolus dose intracoronary (41 patients) or bolus plus intravenous infusion (19 patients) of eptifibatide. In-hospital and follow-up major adverse cardiac events (MACEs) and bleeding rate were recorded and evaluated between groups. RESULTS: Both groups were comparable regarding baseline findings. Bolus only compared to bolus plus infusion group had lower in-hospital (19.5% vs. 31.6%) and follow-up MACE (15.4% vs. 17.6%), lower bleeding in-hospital (14.6% vs. 21.1%) and follow-up (2.4% vs. 5.3%) as well as lower mortality rate in hospital (4.9% vs. 15.8%), but higher follow-up mortality (10.3% vs. 0), but the difference was not significant. CONCLUSIONS: We observed no significant difference regarding bleeding or MACE between intracoronary bolus infusion and bolus plus intravenous infusion of eptifibatide. It seems intracoronary bolus infusion of eptifibatide due to use of lower doses is a better choice in elective PCI to prevent post-PCI MACE.
No takes yet. Share an insight, caveat, or question.
Doustkami et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: